Cross-talk among proteases and matrix in the control of growth factor action

Fibrinolysis and Proteolysis

Volumn 11, Issue 1, 1997, Pages 3-9

  Rifkin, D B ^a  

^a Kaplan Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA;

CONFERENCE PAPER; FIBRINOLYSIS; HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION;

EID: 0030895856     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(97)80003-3     Document Type: Review

References (50)

1. Flaumenhaft R, Rifkin D B. The regulation of growth factor action. Mol Biol Cell 1992; 3: 1057-1065.
2. Naldini L, Tamagnone G, Vigna Z, Sachs M, Hartmann G, Birchmeier W, Daikuhara Y, Tsubouchi H, Blasi F, Comoglio P M. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor. EMBO J 1992; 11 : 4825-4833.
3. Shimora T, Miyazawa K, Komiyama Y, Hiraoki H, Naka D, Morimoto Y, Kitamura N. Activation of hepatocyte growth factor by two homologous proteases, blood coagulation factor Xlla and hepatocyte growth factor activator. Eur J Biochem 1995; 299: 257-261.
4. Matusmoto T, Gargosky S E, Iwasaki K, Rosenfeld R G. dentification and characterization of insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs) and IGFBP proteases in human synovial fluid. J Clin Endocrin Metabol 1996;81: 150-155.
5. Labou C, Silvi C, Segovia B, Benoux M. Interactions des insulinlike growth factors (IGF) et de leurs protéines de liaison avec le système activateur du plasminogene/plasmine dans les cellules osteoblastiques en culture. Annal d'Endocrinologie 1994; 55: 103-107.
6. Nunes I, Munger J E, Harpel J G, Nagano Y, Shapiro R L, Gleizes P-E, Rifkin D B. Structure and activation of the large latent transforming growth factor-β complex. Int J Obesity 1996; 20 (Suppl 3): S4-8.
7. Flaumenhaft R, MoscateUi D, Saksela O, Rifkin D B. Role of extracellular matrix in the action of basic fibroblast growth factor: Matrix as a source of growth factor for long-term stimulation of plasminogen activator and DNA synthesis. J Cell Physiol 1989; 140: 75-81.
8. Park J E, Keller G A, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993; 4: 1317-1326.
9. La Rochelle W J, May-Siroff M, Robbins K C, Aaronson S A. Novel mechanism regulating growth factor association with the cell surface: Identification of a PDGF retention domain. Genes andDev 1991; 5: 1191-1199.
10. Gray A, Dull T J, Ulrich A. Nucleotide sequence of epidermal growth factor cDNA predicts a 120 000 molecular weight protein precursor. Nature 1983; 303: 722-725.
11. Mroczkowski B, Reich M, Chen K, Bell GI, Cohen S. Recombinant human epidermal growth factor precursor is a glycosylated membrane protein with biological activity. Mol Cell Biol 1989; 9: 2771-2778.
12. Derynck R, Roberts A B, Winkler M E, Chen E Y, Goeddel D V. Human transforming growth factor-a: precursor structure and expression in E. coli. Cell 1984; 38: 287-297.
13. Lee D C, Rose T M, Webb N R, Todaro G J. Cloning and sequence analysis of a cDNA for rat transforming growth factora. Nature 1985; 313: 489-491.
14. Anderson D M, Lynian S D, Baird A, Wignall J M, Eisenman J, Rauch C, March C J, Boswell H S, Gimpel, S D, Cosman D, Williams D E. Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane and soluble forms. Cell 1990; 63: 235-243.
15. Basilico C, Moscatelli D. The FGF family of growth factors and oncogenes. Adv Cancer Res 1992; 59: 115-165.
16. Saksela O, Moscatelli D, Sommer A, Rifkin D B. Endothelial cellderived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation by a glycosaminoglycan. J Cell Physiol 1988; 139: 215-228.
17. Sommer A, Rifkin D B. Interaction of heparin with human basic fibroblast growth factor: protection of the angiogenic protein from proteolytic degradation by a glycosaminoglycan. J Cell Physiol 1987; 138: 215-228.
18. Gospodarowicz D, Cheng J. Heparin protects basic and acidic FGF from inactivation. J Cell Physiol 1986; 128: 475-484.
19. Saksela O, Rifkin D B. Release of basic fibroblast growth factorheparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity. J Cell Biol 1990; 110:767-776.
20. Flaumenhaft R, Moscatelli D, Rifkin D B. Heparin and heparan sulfate increase the radius of diffusion and action of basic fibroblast growth factor.] Cell Biol 1990; 111: 1651-1659.
21. Roberts A B, Sporn M B. The transforming growth factor-βs. New York: Springer-Verlag, New York, Inc. 1990.
22. Massague J. The transforming growth factor-β family. Annu Rev Cell Biol 1990; 6: 597-641.
23. Saksela O, Moscatelli D, Rifkin D B. The opposing effects of basic fibroblast growth factor beta on the regulation of plasminogen activator activity in capillary endothelial cells. J Cell Biol 1987; 105: 957-963.
24. Nabel E G, Shum L, Pompüi V J, Yang Z Y, San H, Shu H B, Liptay S, Gold L, Gordon D, Derynck R et al. Direct transfer of transforming growth factor beta 1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sei USA 1993; 90: 10759-10763.
25. Topouzis S, Majesky M. Smooth muscle lineage diversity in the chick embryo: Two types of aortic smooth muscle cells differ in growth and transcriptional responses to transforming growth factor-beta. DevBiol 1996; 178: 430-445.
26. Wakefield L M, Smith D M, Broz S, Jackson M, Levinson A D, Sporn M B. Recombinant TGF-β1 is synthesized as a twocomponent latent complex that shares some structural features with the native platelet latent TGF-βl complex. Growth Factors 1989; 1:203-218.
27. Kanzaki T, Olofsson A, Moren A, Weinstedt C, Hellman U, Miyazono K, Claesson-Welsh L, Heldin C-H. TGF-βl binding protein: A component of the large latent complex of TGF-βl with multiple repeat sequences. Cell 1990; 61: 1051-1061.
28. Rosenbloom J, Abrams W R, Mecham R. Extracellular matrix 4: the elastic fibril. FASEB J 1993; 7: 1208-1218.
29. Zhang H, Apfelroth S D, Hu E, Davis E C, Sanguined C, Bonadio J, Mechan R P, Ramirez F. Structure and expression of fibrillin-2, a novel microfibrillar component preferentially located in elastic matrices. J Cell Biol 1994; 124: 855-863.
30. Brown P, Wakefield L, Levinson A, Sporn M. Physiochemical activation of recombinant latent transforming growth factorbetas 1,2,3. Growth Factors 1990; 3: 35-43.
31. Schultz-Cherry S, Ribeiro S, Gentry L, Murphy-Ulrich J E. Thrombospondin binds and activates the small and large forms of latent transforming growth factor-beta in a chemically defined system. J Biol Chem 1995; 269: 26775-26782.
32. Barcellos-Hoff M H, Derynck R, Tsang M L-S, Weatherbee J A. Transforming growth factor-β activation in irradiated murine mammary glands. J Clin Invest 1994; 93: 892-899.
33. Lyons R M, Gentry L E, Purchio A F, Moses H L. Mechanism of activation of latent recombinant transforming growth factor βl by plasmin. J Cell Biol 1990: 110: 1361-1367.
34. Sato Y, Rifkin D B. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming-βl like molecule by plasmin during co-culture. J CellBiol 1989; 109:309-315.
35. Antonelli-Olridge A, Saunders K B, Smith S R, D'Amore P A. An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad Sei USA 1989; 86: 4544-4548.
36. Odekon L, Blasi F, Rifkin D B. A requirement for receptor-bound urokinase in plasmin-dependent cellular conversion oflatent TGF-β to TGF-β. J Cell Physiol 1994; 158: 398-407.
37. Kojima S, Nara K, Rifkin D B. A requirement for transglutaminase in the activation of latent transforming growth factor-beta in bovine endothelial cells. J Cell Biol 1993; 121: 439-448.
38. Flaumenhaft R, Abe M, Sato Y, Miyazono K, Harpel J G, Heldin C-H, Rifkin D B. Role of the latent TGF-β binding protein in the activation of latent TGF-β by cocultures of endothelial cells and smooth muscle cells. J Cell Biol 1993; 120:995-1002.
39. Dennis P A, Rifkin D B. Cellular activation oflatent transforming growth factor β requires binding to the cationindependent mannose 6-phosphate/insulin-like growth factor type II receptor. Proc Natl Acad Sei USA 1991 ; 88: 580-584.
40. Taipale J, Miyazono K, Heldin C-H, Keski-OjaJ. Latent transforming growth factor-βl associates to fibroblast extracellular matrix via latent TGF-β binding protein. J Cell Biol 1994; 124: 171-181.
41. Kojima S, Rifkin D B. Mechanism of retinoid-induced activation of latent transforming growth factor-β in bovine endothelial cells. J Cell Physiol 1993; 155: 323-332.
42. Folk L A, de Benedetti F, Lohrey N, Birchenall-Roberts M C, Ellingsworth L W, Faltynek C R, Ruscetti F W. Induction of transforming growth factor-β l (TGF-β l ) receptor expression and TGF-β 1 protein production in retinoic acid-treated HL-60: possible TGF-β l-mediated autocrine inhibition. Blood 1991; 77: 1248-1255.
43. Nunes I, Kojima S, Rifkin D B. Effects of endogenously activated transforming growth factor-β on growth and differentiation of retinoic acid-treated HL-60 cells. Cancer Res 1996; 56: 495-499.
44. Flaumenhaft R, Abe M, Mignatti P, Rifkin D B. Basic fibroblast growth factor-induced activation of latent transforming growth factor βin endothelial cells: regulation of plasminogen activator activity. J Cell Biol 1992; 118: 901-909.
45. Lyons R M, Keski-Oja J, Moses H L. Proteolytic activation of latent transforming growth factor-β from fibroblast conditioned medium. J Cell Biol 1998; 106: 1659-1665.
46. Sato Y, Tsuboi R, Lyons R M, Moses H, Rifkin D B. Characterization of the activation of latent TGF-β by cocultures of endothelial cells and pericytes on smooth muscle cells: a selfregulating system. J Cell Biol 1990; 111: 757-783.
47. Nunes I, Shapiro R, Rifkin D B. Characterization of latent TGF-β activation by murine peritoneal macrophages. J Immunol 1995; 1450-1459.
48. Kojima S, Harpel P C, Rifkin D B. Lipoprotein (a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration. J Cell Biol 1991 ; 113 : 1439-1445.
49. Grainger D J, Kemp P R, Liu A C, Lawn R M, Metcalf J C. Activation of transforming growth factor-β is linked in transgenic apolipoprotein (a) mice. Nature 1994; 370: 460-462.
50. Grainger D J, Kemp P R, Metcalfe J C, Liu A C, Lawn R M, Williams N R, Grace A A, Schofield P M, Chauhan A. The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis. Nature Med 1995; 1: 74-79.